CONMED (NYSE:CNMD) Draws Focus After Strong Results
CONMED Corporation (NYSE:CNMD) is drawing market attention due to its strong quarterly financial performance, operational improvements, and sustained demand for its surgical technology solutions. The company's focus on advanced medical technologies and its diversified product portfolio, catering to various medical specialties, have contributed to its growth. Despite mixed market sentiment regarding valuation, CONMED's innovation and financial discipline are strengthening its position in the healthcare industry.
CONMED Corporation (NYSE:CNMD) Given Average Rating of "Reduce" by Brokerages
CONMED Corporation (NYSE:CNMD) has received an average "Reduce" rating from eight brokerages, with an average 12-month price target of $41.40, despite exceeding quarterly expectations with adjusted EPS of $1.38 and revenue of $343.49 million. Shares opened at $51.34, significantly above the analyst consensus, and several institutional investors, including BlackRock and Bank of America, have recently acquired substantial positions in the company.
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
CONMED Corporation (CNMD) is poised for growth due to strong adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, along with increasing robotic procedure volumes and ASC penetration. The company's organic sales growth is healthy, particularly in Orthopedic Surgery and driven by regulatory tailwinds for Buffalo Filter and the growth of BioBrace. However, challenges include moderating AirSeal growth expectations and ongoing tariff headwinds that impact earnings despite a recent refund.
CONMED Corporation $CNMD Stock Holdings Lessened by Amundi
Amundi significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 99.7% in the first quarter, selling over 2.29 million shares. Despite this, other major investors increased their holdings, and CONMED surpassed earnings and revenue expectations. However, analysts maintain a cautious "Reduce" rating with a price target below the current stock price.
CONMED (NYSE:CNMD) Upgraded to Hold at Zacks Research
Zacks Research has upgraded CONMED (NYSE:CNMD) from a "strong sell" to a "hold" rating, despite the broader analyst consensus remaining at "Reduce" with an average price target of $41.40. This upgrade follows CONMED's strong quarterly earnings report, where it exceeded EPS and revenue estimates, with EPS of $1.38 against an estimated $1.11, and revenue of $343.49 million versus the $337.60 million consensus. Several institutional investors also increased their holdings in CONMED during the first quarter.
CONMED Corporation $CNMD Shares Sold by Bank of America Corp DE
Bank of America Corp DE significantly reduced its stake in CONMED Corporation ($CNMD) by 57.6% in the first quarter, selling 1.9 million shares but still retaining 1.4 million shares valued at approximately $49.6 million. Despite CONMED beating Q1 earnings estimates with $1.38 EPS and revenue of $343.5 million, analyst sentiment remains cautious, with a consensus "Reduce" rating and an average price target below its current trading price. Other institutional investors like Vanguard and Dimensional Fund Advisors have adjusted their holdings, with some increasing and others initiating new positions.
Conmed Corp (CNMD) Stock News Today
This page provides an overview of Conmed Corp (CNMD) stock information, including its current market price, market capitalization, and P/E ratio. It also indicates that more news and analysis regarding the company's stock, earnings, and analyst ratings will be available soon. The platform, TradingKey, offers tools for investment decisions and advises users that the information provided is general and not financial advice.
Conmed Corp (CNMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
Conmed Corp (CNMD) has an earnings forecast score of 5.71, ranking 183 out of 200 in its industry, with an average analyst price target of $52.00. Analysts currently recommend a "Hold" rating for the stock. The company's expected revenue for the next quarter is $336.23M, and its previous quarter's EPS was $0.45, with an expectation of $1.00 for the upcoming quarter.
CONMED Corporation (CNMD) Stock Forecasts
Argus has raised its target price for CONMED Corporation (CNMD) to $53.00. The medical equipment company, based in Utica, New York, specializes in sports medicine procedures and general surgeries. The current stock price for CNMD is $49.12.
CONMED Corporation $CNMD Shares Sold by Edgestream Partners L.P.
Edgestream Partners L.P. significantly reduced its stake in CONMED Corporation (NYSE:CNMD) during the first quarter, selling 87.4% of its shares. Despite this, CONMED reported strong quarterly earnings, surpassing analyst expectations for both EPS and revenue, and maintained its fiscal 2026 EPS guidance. Analyst sentiment for CONMED remains cautious, with a consensus "Reduce" rating and an average price target of $41.40.
CONMED Corp Q2 2026: Revenue $343.5M, EPS $0.77— 10-Q Summary
CONMED Corp reported its Q2 2026 financial results, with revenue reaching $343.5 million, remaining relatively flat year-over-year. The company saw an increase in net income to $23.1 million and diluted earnings per share to $0.77. Growth was primarily driven by orthopedic sales, despite the company's exit from the gastroenterology market.
Bank of New York Mellon Corp Decreases Stock Holdings in CONMED Corporation $CNMD
Bank of New York Mellon Corp significantly reduced its stake in CONMED Corporation (NYSE:CNMD) by 51.9% in the first quarter, selling 312,691 shares and now owning 289,234 shares valued at $10.23 million. Other institutional investors also adjusted their positions in CONMED, with some increasing and others decreasing their holdings. The article also provides recent analyst ratings, price targets, and discusses CONMED's positive Q2 results and increased guidance, despite some neutral and negative sentiment regarding its valuation and modest revenue growth.
Stocks making big moves this week: Huron, Sherwin-Williams, PROG, CONMED, and Freshworks
This article highlights five companies – Huron, Sherwin-Williams, PROG, CONMED, and Freshworks – that experienced significant stock movements this week due to strong financial results, raised outlooks, or key appointments. Huron, Sherwin-Williams, and CONMED saw their stocks rise after beating analyst expectations and increasing their full-year guidance. PROG Holdings' stock fell despite beating expectations and raising guidance, while Freshworks rose after announcing a new Chief Product and Technology Officer.
Conmed Corp : JP Morgan Raises Target Price t
This article reports that JP Morgan has increased its target price for Conmed Corp. The specific details of the new target price and the rationale behind the upgrade are not provided in the snippet.
CONMED (NYSE:CNMD) Given New $46.00 Price Target at Wells Fargo & Company
Wells Fargo & Company has raised its price target for CONMED (NYSE:CNMD) to $46.00 from $39.00 while maintaining an "equal weight" rating. This adjustment follows CONMED's strong Q2 2026 earnings, where the company surpassed consensus estimates for both EPS and revenue, and provided optimistic full-year guidance. Despite a reported revenue growth of only 0.3%, organic sales increased by 6% after excluding the impact of strategic product exits.
CONMED CORP : JEFFERIES RAISES TARGET PRICE TO $49 FROM $40
Jefferies has raised its target price for CONMED CORP (CNMD.N) to $49 from $40. This article, published by Reuters, briefly reports on this updated analyst rating. The content is for informational purposes and not intended as investment advice.
CONMED Q2 Earnings and Revenues Beat Estimates, Gross Margin Expands
CONMED Corporation (CNMD) reported strong second-quarter 2026 results, with adjusted EPS of $1.38 and revenues of $343.5 million, both exceeding Zacks Consensus Estimates. The company saw organic constant-currency revenue growth of 6% driven by its AirSeal, Buffalo Filter, and BioBrace platforms, and an adjusted gross margin expansion to 59.5%. Despite some headwinds like the GI portfolio exit and flat domestic orthopedic sales, CONMED raised its adjusted EPS outlook for 2026, anticipating continued organic growth.
Conmed: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for Conmed. No specific financial details or further information are available within the provided content.
CONMED (NYSE: CNMD) lifts Q2 profit, exits gastro line and cuts notes
CONMED Corporation reported increased net income and diluted EPS for Q2 2026, reaching $23.1 million and $0.77 respectively, despite largely flat net sales year-over-year. The company's gross margin expanded to 57.5%, boosted by an IEEPA tariff refund, though partially offset by inventory write-downs due to discontinued gastroenterology products. CONMED also repurchased a significant portion of its convertible notes, funding this through a new term loan and revolver borrowings, while suspending dividend payments and exiting its gastroenterology business.
Conmed: Q2 Earnings Snapshot
Conmed reported its Q2 earnings, with net income totaling $4.8 million, or $0.16 per share. The medical technology company's adjusted earnings were 65 cents per share, surpassing Wall Street expectations. Revenue reached $326.6 million, also exceeding analyst forecasts.
CONMED updates 2026 adjusted EPS outlook to $4.48-$4.60 after Q2
CONMED Corporation reported strong second-quarter 2026 financial results, with sales of $343.5 million and adjusted diluted EPS of $1.38, exceeding expectations. The company updated its full-year 2026 financial guidance for adjusted diluted EPS to range from $4.48 to $4.60, reflecting its Q2 performance and an updated outlook for the remainder of the year. This improved outlook is attributed to organic constant currency net sales growth across both Orthopedic Surgery and General Surgery product lines, and strategic portfolio optimization.
CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
CONMED Corporation reported its second quarter 2026 financial results, with sales of $343.5 million, a 0.3% year-over-year increase, and adjusted diluted EPS up 20.0% to $1.38. The company updated its full-year 2026 financial guidance, anticipating net sales between $1.358 billion and $1.373 billion, and adjusted diluted EPS between $4.48 and $4.60. Key operational announcements included new board and CFO appointments, and an expanded indication for its AirSeal® Robotic Solution.
CONMED earnings ahead as investors weigh strategic sale prospects By Investing.com
CONMED Corporation is expected to report second-quarter earnings, with analysts anticipating $1.11 per share on $337.5 million in revenue. The medical device maker is also exploring a potential sale, which Bloomberg reported in mid-July, causing shares to rise significantly. Investors will be closely watching management's commentary on the strategic review and the company's ability to demonstrate organic growth in key platforms.
CONMED Number of Employees 2026 | Employee Count & Headcount Data
CONMED Corp. (CNMD) has approximately 3,868 employees worldwide as of March 2026, marking a 0.2% decline from 2023. The company, headquartered in Largo, Florida, is actively hiring with 212 job postings in 2026, and its workforce is primarily concentrated in the United States. Employee sentiment is neutral but declining, with an average salary of $88,679 globally.
Conmed Corp (CNMD) Institutional Confidence
Conmed Corp (CNMD) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion has seen a quarter-over-quarter decrease of 16.04%, with HOTCHKIS & WILEY as the largest institutional holder, possessing 1.05% of outstanding shares. Various institutional investors have adjusted their holdings, with some increasing and others decreasing their stakes.
Conmed Corp (CNMD) Cash Flow
This article provides a detailed historical cash flow statement for Conmed Corp (CNMD), covering quarterly and annual data for operating, investing, and financing activities. It also includes definitions and explanations of key cash flow terms like operating cash flow, investing cash flow, financing cash flow, and free cash flow, along with recent figures for CNMD. The data helps evaluate the company's financial soundness and stability.
Conmed Corp (CNMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Conmed Corp (CNMD), listing major institutional holders and their respective proportions. It also presents a breakdown of shareholder types such as investment advisors and hedge funds, as well as institutional shareholding activity over several quarters. Additionally, the article identifies related ETFs that hold CNMD shares.
Conmed Corp (CNMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Conmed Corp (CNMD), categorizing its revenue by business segment and geographical region. For the reported period, General Surgery accounted for 58.20% of total revenue, while Orthopedic Surgery contributed 41.80%. Geographically, the United States was the largest revenue generator at 56.34%, followed by Europe & Middle East & Africa and Asia Pacific.
Conmed Corp (CNMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Conmed Corp (CNMD), indicating a current earnings forecast score of 6.00 and ranking 174 out of 200 in its industry. Analysts have set an average price target of $52.00, with a consensus "Hold" rating. The report also details expected revenue, past and future EPS, and peer comparisons.
CNMD|Conmed Corp|Price:43.500|Chg%:+0.820
This article provides a comprehensive stock analysis of Conmed Corp (CNMD), highlighting its stable fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. It notes strong institutional ownership, recent "Hold" ratings from analysts with a target price of $38.80, and a sideways trading pattern suggesting suitability for range-bound swing trading. The analysis also covers the company's product lines in orthopedic and general surgery, its high dividend payout, and institutional selling trends.
CNMD|Conmed Corp|Price:42.730|Chg%:+1.460
This article provides a detailed financial overview of Conmed Corp (CNMD), including its stock price, market capitalization, P/E ratio, and upcoming earnings date. It presents a comprehensive look at the company's financial indicators such as EPS, revenue, net profit, margins, and debt-to-assets ratio across multiple quarters and fiscal years. The report also includes FAQs offering quick answers to key financial metrics based on the FY2025 earnings report.
Conmed Corp (CNMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of dividend payouts for Conmed Corp (CNMD), detailing specific dividend events, including record dates, payment dates, and ex-dividend dates from 2023 through 2025. It indicates that Conmed Corp has distributed a total of 96.37 million USD in dividends over the past five years. The current stock price, market capitalization, and P/E ratio are also mentioned.
CONMED Expands AirSeal Robotic Solution for da Vinci 5 Hex Cannula
CONMED (CNMD) announced FDA expansion for its AirSeal Robotic Solution to be used with Intuitive Surgical's (ISRG) 8 mm hex cannulas on the da Vinci 5 robotic surgery platform, broadening its compatibility across all da Vinci systems. This expansion is expected to enhance surgical workflows, improve patient outcomes, and strengthen CONMED's AirSeal portfolio's long-term growth potential. The market for insufflation devices is projected to grow, with CONMED poised to benefit from increasing adoption of minimally invasive surgeries.
Conmed’s AirSeal Robotic Solution OK’ed for Intuitive da Vinci 5 Hex Cannula
Conmed Corp. has received expanded indication for its AirSeal robotic solution, allowing it to be used with Intuitive’s 8 mm hex cannulas for the da Vinci 5 platform. This new approval builds on its existing compatibility with Intuitive’s da Vinci 8mm round cannulas, offering surgeons and hospitals greater flexibility. The AirSeal system is designed to enhance patient outcomes through stable pneumoperitoneum, continuous smoke evacuation, and low-pressure insufflation, strengthening Conmed's position in the robotic surgery market.
CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula
CONMED Corporation's AirSeal Robotic Solution has received an expanded FDA indication for use with Intuitive's 8 mm hex cannulas, specifically for the da Vinci 5 platform. This expansion means the AirSeal solution is now compatible across Intuitive's entire da Vinci robotic system portfolio, including the X, Xi, and 5 models. The company expects this to provide clarity in the marketplace and support consistent surgical workflows, reinforcing AirSeal's position in the robotic surgery market.
CONMED expands AirSeal compatibility to da Vinci 5 platform
CONMED Corporation (NYSE:CNMD) announced an expanded indication for its AirSeal Robotic Solution, making it compatible with Intuitive's 8 mm hex cannulas used in the da Vinci 5 platform. This expansion means the AirSeal solution can now be used across all of Intuitive's da Vinci robotic systems, including the da Vinci X, Xi, and 5. The AirSeal system provides stable pneumoperitoneum, continuous smoke evacuation, and low-pressure insufflation during robotic surgical procedures.
Bessemer Group Inc. Purchases 36,940 Shares of CONMED Corporation $CNMD
Bessemer Group Inc. increased its stake in CONMED Corporation (NYSE:CNMD) by 46.5% during the first quarter, acquiring an additional 36,940 shares to bring its total holding to 116,429 shares, valued at approximately $4.1 million. This increase occurred despite CONMED's mixed Q1 results, which beat EPS and revenue estimates but showed a slight year-over-year revenue decline. Wall Street sentiment remains cautious, with a "Reduce" consensus rating and an average price target below the stock's current trading level.
Allspring Global Investments Holdings LLC Increases Holdings in CONMED Corporation $CNMD
Allspring Global Investments Holdings LLC significantly increased its stake in CONMED Corporation (NYSE:CNMD) by 39.9% in the first quarter, bringing its total holding to 582,733 shares valued at approximately $20.7 million. This increase comes despite several analysts maintaining a cautious outlook on CONMED, with an overall consensus rating of “Reduce” and a target price of $38.80. CONMED recently reported better-than-expected quarterly earnings and revenue, though sales were down year-over-year.
In 40 Robotic Prostatectomies, AirSeal Had Fewer Nociceptive Events per Hour
CONMED Corporation announced that its AirSeal® Insufflation System demonstrated superior performance over Stryker's PneumoClear Insufflator in a randomized controlled clinical trial involving 40 robotic prostatectomy patients. The trial found that the AirSeal arm had significantly fewer intraoperative nociceptive events per hour, shorter procedure and console times, and less blood loss. These findings will be presented at the Society of Robotic Surgery (SRS) 2026 Annual Meeting.
CONMED (NYSE:CNMD) Stock Rating Upgraded by Wall Street Zen
Wall Street Zen has upgraded CONMED (NYSE:CNMD) stock from "hold" to "buy," despite a mixed outlook from other analysts who largely rate it as "Reduce" with an average target price of $38.80. This upgrade comes after CONMED surpassed quarterly earnings and revenue estimates, reporting $0.89 EPS and $317.05 million in revenue, though year-over-year sales saw a slight decline. The article also details institutional investor activity and provides an overview of CONMED's financial performance and company profile.
CNMD5600366 Bond Profile — Key Metrics
This article provides the key metrics for the CONMED Corporation's 2.25% bond, CNMD5600366, maturing on June 15, 2027. It details the issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. Additionally, it offers a brief company profile of CONMED Corp., a medical technology company.
CONMED files Form 3 for EVP, CFO John Gallagher`
CONMED has filed a Form 3 for John E. Gallagher, officially naming him as Executive Vice President and Chief Financial Officer, effective July 15, 2026. This news brief, generated by Public Technologies (PUBT) using AI, is based on the original content published by CONMED Corporation via the SEC's EDGAR system.
Form 4 CONMED Corporation For: 17 July By Investing.com
This article reports on a Form 4 filing for CONMED Corporation (NYSE: CNMD) made on July 17. Form 4 filings are used to report changes in beneficial ownership of securities by company insiders. The brief notice from Investing.com indicates that such a filing was made on the specified date.
CONMED Corp (NYSE: CNMD) grants CFO stock options and RSUs
CONMED Corp (NYSE: CNMD) has granted its Executive Vice President and CFO, John E. Gallagher, stock options and Restricted Stock Units (RSUs) as part of the company's 2025 Long-Term Incentive Plan. Gallagher received 30,536 stock options with an exercise price of $42.79 per share and two RSU grants totaling 26,875 and 35,054 shares. These awards are subject to vesting schedules, with RSUs vesting over three years and stock options over four years, aligning the CFO's incentives with the company's long-term performance.
ETFs Investing in CONMED Corporation Stocks
This article lists numerous Exchange Traded Funds (ETFs) that hold shares of CONMED Corporation. It provides a detailed table with each ETF's market value, weight of CONMED stock, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The information helps investors identify funds offering diversified exposure to small-cap and healthcare sectors that include CONMED Corporation.
Form 4 CONMED Corporation For: 17 July By Investing.com
This article concerns a Form 4 filing for CONMED Corporation (CNMD) related to activity on July 17. Form 4s detail changes in beneficial ownership of company stock by insiders. The article was published by Investing.com.
Understanding Momentum Shifts in (CNMD)
This article analyzes momentum shifts for Conmed Corp. (CNMD) using AI models, outlining near- and mid-term strong sentiment but a weak long-term outlook. It provides specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The
Needham reiterates Hold on Conmed stock amid sale exploration
Needham has reiterated a Hold rating on Conmed (NYSE:CNMD) after reports surfaced that the medical device company is exploring a potential sale. The firm anticipates offers could come at a significant premium, citing Conmed's mid-single-digit growth, strong recurring revenue, and undervalued status. Potential acquirers include larger companies like Zimmer Biomet or private equity firms.
CONMED (CNMD) Stock Trades Up, Here Is Why
Shares of medical technology company CONMED (CNMD) jumped 9% after reports indicated the company is exploring a potential sale due to interest from private equity firms. This surge occurred despite a recent downgrade by BofA Securities due to concerns about future growth and revised financial estimates. Currently, CONMED's stock is up 3.2% year-to-date, but remains significantly below its 52-week high.
Conmed Surges Within Striking Distance Of A Breakout On Buyout Rumors
Conmed (CNMD) stock surged ahead today due to rumors that the medical technology company is considering a sale. An analyst at Needham noted that a sale would make sense given Conmed's steady growth, strong recurring revenue, and undervalued stock. Conmed specializes in surgical devices, equipment, and patient monitoring systems, and a premium of 30% to 50% on its stock is anticipated.
